Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Abstract

SNF'ing out antitumor immunity Immune checkpoint inhibitors induce durable tumor regressions in some, but not all, cancer patients. Understanding the mechanisms that determine tumor sensitivity to these drugs could potentially expand the number of patients who benefit (see the Perspective by Ghorani and Quezada). Pan et al. discovered that tumor cells in which a specific SWI/SNF chromatin remodeling complex had been experimentally inactivated were more sensitive to T cell–mediated killing. The cells were more responsive to interferon-γ, leading to increased secretion of cytokines that promote antitumor immunity. Miao et al. examined the genomic features of tumors from patients with metastatic renal cell carcinoma who had been treated with immune checkpoint inhibitors. Tumors harboring inactivating mutations in PBRM1 , which encodes a subunit of the same SWI/SNF complex, were more likely to respond to the drugs. Science , this issue p. 770 , p. 801 ; see also p. 745

Keywords

Affiliated Institutions

• Columbia University Irving Medical Center US
• Dana-Farber Cancer Institute US
• Cornell University US
• Bristol-Myers Squibb (United States) US
• Johns Hopkins Medicine US
• Johns Hopkins University US
• Broad Institute US
• Howard Hughes Medical Institute US
• Memorial Sloan Kettering Cancer Center US
• Mayo Clinic in Arizona US
• Massachusetts Institute of Technology US

Related Publications